] . (2017). Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med, 376(10), 928-938. presented at the 2017 03 09. doi:10.1056/NEJMoa1410863
. (2015). Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One, 10(4), e0123969. presented at the 2015. doi:10.1371/journal.pone.0123969
. (2015). Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis, 211(4), 549-57. presented at the 2015 Feb 15. doi:10.1093/infdis/jiu511
. (2015). Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet, 385(9977), 1545-54. presented at the 2015 Apr 18. doi:10.1016/S0140-6736(14)62385-0
. (2014). Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, 384(9959), 2046-52. presented at the 2014 Dec 06. doi:10.1016/S0140-6736(14)61185-5
. (2013). Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis, 208(3), 418-22. presented at the 2013 Aug 01. doi:10.1093/infdis/jit180